The case for routine use of adjuvant therapy in pancreatic cancer.
Publication/Presentation Date
6-1-2007
Abstract
Pancreatic cancer is a devastating disease with a poor prognosis for most patients. Surgical resection remains the cornerstone of treatment, providing the only realistic hope of long-term survival. Even with optimal surgical management, 5-year survival averages 15% to 20% for resectable disease. Progress is being made, however. Currently, the benefits of postoperative therapy for resected pancreatic ductal adenocarcinoma appear clear, and recommendations for such therapy appear to us to be well justified. Additional benefit to patients awaits the development of new agents, molecular targeted drugs, and novel approaches such as immunotherapy.
Volume
95
Issue
7
First Page
597
Last Page
603
ISSN
0022-4790
Published In/Presented At
Kennedy, E. P., & Yeo, C. J. (2007). The case for routine use of adjuvant therapy in pancreatic cancer. Journal of surgical oncology, 95(7), 597–603. https://doi.org/10.1002/jso.20719
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
17230543
Department(s)
Administration and Leadership
Document Type
Article